Beamion LUNG-1 And LUNG-2: The Zongertinib Clinical Program in Patients with Non-Small Cell Lung Cancer and HER2 Mutations

被引：0
|
作者：
Wu, Y. -L. [1 ]
Opdam, F. [2 ]
Yamamoto, N. [3 ]
Yoshida, T. [3 ]
Heymach, J. [4 ]
机构：
[1] Southern Med Univ, Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] Natl Canc Ctr, Chuo Ku, Tokyo, Japan
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.12D.06
引用
收藏
页码：S348 / S348
页数：1
相关论文
共 50 条
  • [1] Zongertinib in patients with HER2-mutant NSCLC: Updated analysis of beamion LUNG-1
    Yamamoto, N.
    Tu, H.
    Ahn, M-J.
    Yoh, K.
    Zugazagoitia, J.
    Smit, E. F.
    Wu, Y-L.
    Planchard, D.
    Cho, B. C.
    Wehler, B.
    Zhao, Y.
    Nadal, E.
    Lin, G.
    von Wangenheim, U.
    Rohrbacher, M.
    Sadrolhefazi, B.
    Heymach, J.
    Ruiter, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S1623 - S1624
  • [2] A phase 3 randomized controlled trial of zongertinib (BI 1810631) compared with standard of care in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer harboring HER2 tyrosine kinase domain mutations: Beamion LUNG-2
    Wu, Yi-Long
    Johnson, Melissa
    Soo, Ross
    Baktash, Navid
    Maier, Daniela
    Eigenbrod-Giese, Sabina
    Yoshida, Tatsuya
    CANCER RESEARCH, 2024, 84 (07)
  • [3] HER2 mutations in Chinese patients with non-small cell lung cancer
    Song, Zhengbo
    Yu, Xinmin
    Shi, Zhiyong
    Zhao, Jun
    Zhang, Yiping
    ONCOTARGET, 2016, 7 (47) : 78152 - 78158
  • [4] HER2 Mutations in Chinese Patients with Non-Small Cell Lung Cancer
    Song, Zhengbo
    Zhang, Yiping
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S494 - S495
  • [5] Primary Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2 Mutation-Positive NSCLC
    Ruiter, G.
    Tu, H. -Y.
    Ahn, M. -J.
    Yoh, K.
    Zugazagoitia, J.
    Smit, E.
    Wu, Y. -L.
    Planchard, D.
    Cho, B. -C.
    Wehler, B.
    Zhao, Y.
    von Wangenheim, U.
    Rohrbacher, M.
    Sadrolhefazi, B.
    Lin, G.
    Yu, Y.
    Nadal, E.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S4 - S5
  • [6] Molecular Characteristics of HER2 Mutations in Non-Small Cell Lung Cancer
    Wei, X.
    Gao, X.
    Zhang, X.
    Chen, Z.
    Wu, Y.
    Zhou, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S848 - S849
  • [7] Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations
    Johnson, Melissa Lynne
    Soo, Ross A.
    Wu, Yi-Long
    Baktash, Navid
    Maier, Daniela
    Eigenbrod-Giese, Sabina
    Yoshida, Tatsuya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors
    Heymach, John
    Yamamoto, Noboru
    Opdam, Frans
    Barve, Minal
    Tu, Hai-Yan
    Wu, Yi-Long
    Schroeter, Lukas
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Berz, David
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E1 - E1
  • [9] Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report
    Illini, Oliver
    Lang-Stoeberl, Anna Sophie
    Fabikan, Hannah
    Weinlinger, Christoph
    Valipour, Arschang
    Hochmair, Maximilian J.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 42
  • [10] HER-2 Mutations in Non-Small Cell Lung Cancer
    Sen, Erdem
    Yavas, Guler
    Ata, Ozlem
    MEDICAL JOURNAL OF BAKIRKOY, 2018, 14 (03) : 322 - 325
12345